Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Other Dec 10 | 2021Lilly Partners with Regor Therapeutics for Metabolic Drug DiscoveryPurchase Blast
$599
Posted in: Other Dec 09 | 2021Ionis Hosts 2022 Investor Day; Intercept Withdraws OCA MAA in NASHPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other Dec 07 | 2021vTv Therapeutics to Reduce Workforce by 65%; Innovent Announces Positive Results for Ph1 GLP-1/GCG from Lilly; Nemaura Completes Initial Shipment of CGM Devices to MySugarWatch DuoPack LimitedPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other Dec 06 | 2021Tandem Hosts 2021 R&D Webinar; FDA Accepts IND for G&L's Novel GLP-1 Analogue; BD Announces Name of Diabetes Spin Off CompanyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Dec 03 | 2021Abbott Sues Dexcom Over Breached Settlement Agreement; Bigfoot Clinical Hub Improvements; Hygieia Raises $17M in Series B; ViaCyte’s Ph1/2 VC-02 Preliminary Results Published; Dario Announces New Employer and Provider ContractsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Nov 30 | 2021Sciwind Biosciences Acquires Worldwide Rights to Sanofi's GIP Receptor Agonists; Diamyd Pauses Initiation of Ph3 DIAGNODE-3 Trial; AMF Medical’s Sigi Patch Pump Receives Breakthrough Device Designation; FDA Authorizes Sample Size Expansion for Fractyl Health’s Revitalize-1 Pivotal TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Other Nov 29 | 2021Libre 2 Android App Cleared in US; CytoDyn Reports Positive Leronlimab NASH Data; Kadimastem Raises $3.2 to Support T1DM Cell Therapy Development; Integrity Applications Changes Name to GlucoTrack, Inc.Purchase Blast
$599
Posted in: Other Nov 24 | 2021Happy Thanksgiving from CVRM! Coming Soon in December...Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other Nov 23 | 2021Medtronic CY Q3 '21 (FY Q2 '22) Earnings Update; HAGAR’s GWave Receives Breakthrough Device Designation; Oramed Randomizes 75% of Patients in Oral Insulin Trial; Beyond Type 1 Launches Web Platform in ArabicPurchase Blast
$599
Posted in: Dual/triple agonist, Other Nov 22 | 2021Intarcia Files Notice of Opportunity for a Hearing; Provention Bio Advances popPK Model for Teplizumab; Zealand Announces Dapiglutide Topline ResultsPurchase Blast
$599
Posted in: Other Nov 18 | 2021Teladoc Hosts 2021 Investor Day; Better Therapeutics Pivotal BT-001 Trial for T2DM Completes Enrollment; Dario Announces New Employer ContractsPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Nov 16 | 2021Viatris/Biocon Launch Interchangeable Semglee in US; Lexicon Presents SOLOIST/SCORED Renal Subcuts at AHA; CRISPR/ViaCyte to Initiate Ph1 Trial in T1DM; Innovation Zed Announces InsulCheck DOSE 2022 Launch; Nemaura and Dario Q3 '21 Earnings UpdatesPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other Nov 12 | 2021Novo’s High-Dose Ozempic Receives Positive CHMP Opinion; Movano Q3 '21 Earnings UpdatePurchase Blast
$599
Posted in: Other, SGLT2i Nov 12 | 2021AZ Q3 ’21 Earnings Update; J&J to Split Consumer and Pharma/Med Device BusinessPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Nov 11 | 2021BI/Lilly’s Jardiance Receives FDA Priority Review; Novo’s Wegovy Receives Positive CHMP Opinion; Merck/Bayer Initiate New Ph3 Verquvo Study; Dario Enters Three New Commercial Agreements; Gmax Administers First in Human Dose of GMA106 in Ph1 Obesity Study; Metacrine and Zealand Q3 ’21 Earnings UpdatesPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
